Skip to main content

Table 4 Dosimetric evaluation for rectum according to spacer

From: Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

*

Non-spacer group

(8 patients)

Spacer group

(15 patients)

P value

Prostate volume (cc)

66.48 ± 22.07

(41.30–109.35)

57.57 ± 20.78

(25.73–95.96)

0.333

Rectal volume (cc)

191.7 ± 30.9

(154.9–231.1)

172.8 ± 23.1

(135.2–206.9)

0.131

Rectum Dmax

74.15 ± 0.87

(73.00–76.0)

73.15 ± 0.89

(71.02–74.0)

0.013

Rectum Dmean

24.10 ± 7.56

(12.66–36.39)

19.1 ± 4.6

(9.73–25.75)

0.065

Rectum Dmedian

13.44 ± 11.88

(2.13–38.41)

7.4 ± 5.02

(1.6–18.59)

0.238

RV73Gy

0.67 ± 0.58

(0.05–1.53)

0.12 ± 0.13

(0–0.42)

0.007

RV72Gy

3.34 ± 1.89

(1.12–6.66)

1.19 ± 1.0

(0.00–3.04)

0.005

RV70Gy

7.56 ± 2.97

(2.45–10.72)

3.078 ± 2.23

(0.05–6.87)

0.001

RV68.4 Gy (95% of dose)

9.52 ± 3.41

(3.32–12.64)

4.17 ± 2.71

(0.15–8.8)

0.002

RV66Gy

11.95 ± 4.27

(4.27–15.83)

5.67 ± 3.31

(0.37–10.86)

0.003

RV65Gy

12.90 ± 4.57

(4.93–17.69)

6.25 ± 3.52

(0.51–11.63)

0.003

RV62Gy

15.51 ± 5.86

(5.76–3.25)

8.1 ± 4.18

(1.05–14.08)

0.005

RV60Gy

17.11 ± 6.12

(6.46–26.75)

9.49 ± 4.32

(1.82–15.40)

0.005

RV55Gy

20.95 ± 8.1

(7.95–33.46)

13.22 ± 4.74

(3.12–18.74)

0.016

RV50Gy

24.18 ± 9.20

(9.6–38.92)

16.49 ± 5.38

(4.57–22.76)

0.019

RV40Gy

29.96 ± 11.1

(12.97–48.65)

22.15 ± 6.48

(8.26–32.02)

0.056

RV30Gy

35.49 ± 12.51

(16.84–56.85)

27.91 ± 7.49

(12.61–40.32)

0.065

RV20Gy

41.75 ± 13.72

(21.62–64.97)

34.48 ± 8.39

(18.25–48.8)

0.149

RV10Gy

50.42 ± 14.65

(29.74–74.97)

43.85 ± 9.44

(26.67–59.37)

0.231

  1. Significance P value < 0.05 (Bold)
  2. *Dose in Gy; RVX Gy = Percentage of rectal volume received X dose; all result are presented in mean ± SD (range)